3-(dimethylamino)-1-(5-methyl-2-furanyl)-2-propen-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(dimethylamino)-1-(5-methyl-2-furanyl)-2-propen-1-one
• 英文别名: (Z)-3-(dimethylamino)-1-(5-methylfuran-2-yl)prop-2-en-1-one
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: XWBWCQRTMKRLQZ-SREVYHEPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  33.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-phenylguanidine hydrochloride 、 3-(dimethylamino)-1-(5-methyl-2-furanyl)-2-propen-1-one 在 sodium carbonate 作用下， 以 乙二醇甲醚 为溶剂， 反应 25.0h， 以60%的产率得到[4-(5-Methyl-furan-2-yl)-pyrimidin-2-yl]-phenyl-amine
  参考文献：
  名称：

  Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors

  摘要：

  The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders. Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy. Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release. These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines. After examining a large number of analogs, N-[3-(1H-imidazol-1-yl)phenyl]-4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.

  DOI：

  10.1021/jm00071a002
• 作为产物：
  描述：

  5-甲基-2-乙酰基呋喃 、 N,N-二甲基甲酰胺二甲基缩醛 反应 30.0h， 生成 3-(dimethylamino)-1-(5-methyl-2-furanyl)-2-propen-1-one
  参考文献：
  名称：

  Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors

  摘要：

  The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders. Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy. Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release. These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines. After examining a large number of analogs, N-[3-(1H-imidazol-1-yl)phenyl]-4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.

  DOI：

  10.1021/jm00071a002

文献信息

• [EN] SUBSTITUTED UREA COMPOUND AND PREPARATION METHOD AND USE THEREOF<br/>[FR] COMPOSÉ D'URÉE SUBSTITUÉ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 取代脲类化合物及其制备方法和用途
  申请人：SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

  公开号：WO2019141096A1

  公开（公告）日：2019-07-25

  提供取代脲类化合物及其制备方法和用途，更具体地涉及所述取代脲类化合物或其药学上可接受的盐、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药。提供所述化合物的制备方法、中间体、包含所述化合物的药物组合物以及它们的治疗用途。所述的化合物或其药物组合物能够抑制腺苷A2a受体活性，可用于治疗或预防与腺苷A2a受体有关疾病，尤其是用于治疗肿瘤。